Sangamo BioSciences Inc (NASDAQ:SGMO)

14.15
Delayed Data
As of Apr 20
 -0.35 / -2.41%
Today’s Change
9.39
Today|||52-Week Range
19.25
-6.97%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.0B

Company Description

Sangamo BioSciences, Inc. is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. It is engaged in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. The company has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic for the treatment of HIV/AIDS. Its other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Its product pipeline consists of SB-728 and SB-313. Sangamo BioSciences was founded by Lanphier O. Edward II on June 22, 1995 and is headquartered in Richmond, CA.

Contact Information

Sangamo BioSciences, Inc.
Point Richmond Tech Center II
Richmond California 94804
P:(510) 970-6000
Investor Relations:
15109706000271

Employees

Shareholders

Individual stakeholders8.78%
Other institutional38.81%
Mutual fund holders33.72%

Top Executives

Edward O. LanphierPresident, Chief Executive Officer & Director
Henry Ward WolffChief Financial Officer & Executive Vice President
Philip D. GregoryChief Scientific Officer & Senior VP-Research
Dale G. AndoChief Medical Officer & VP-Therapeutic Development
Geoffrey M. NicholExecutive Vice President-Research & Development

To view my watchlist

Not a member yet?

Sign up now for a free account